Search

Displaying results 3101 - 3110 of 10000 in total
  1. Drug

    Favipiravir

    go.drugbank.com/drugs/DB12466
    ApprovedInvestigational

    Discovered by Toyama Chemical Co., Ltd. in Japan, favipiravir is a modified pyrazine analog that was initially approved for therapeutic use in resistant cases of influenza. … [A191688,A191772,A191775] Not only does favipiravir inhibit replication of influenza A and B, but the drug has shown promise in the treatment of avian influenza, and may be an alternative option for

    Products: L-VIR
  2. Drug

    Butorphanol

    go.drugbank.com/drugs/DB00611
    ApprovedIllicitVet approved

    A synthetic morphinan analgesic with narcotic antagonist action. It is used in the management of severe pain.

    Synonyms: (−)-N-cyclobutylmethyl-3,14-dihydroxymorphinan
  3. Drug

    Ensitrelvir

    go.drugbank.com/drugs/DB18834
    ApprovedInvestigational

    Ensitrelvir is under investigation in clinical trial NCT05605093 (Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)).

  4. Drug

    Tositumomab

    go.drugbank.com/drugs/DB00081
    ApprovedWithdrawn

    It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine).

  5. Drug

    Brivaracetam

    go.drugbank.com/drugs/DB05541
    ApprovedInvestigational

    Brivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam [A19184]. … Briviact received FDA approval on February 19, 2016 [L760].

  6. Drug

    Mecamylamine

    go.drugbank.com/drugs/DB00657
    ApprovedInvestigational

    Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool. … A nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier.

  7. Drug

    Imidafenacin

    go.drugbank.com/drugs/DB09262
    Investigational

    Imidafenacin is an antispasmodic agent with anticholinergic effects. It antagonizes muscarinic receptors in the bladder to reduce the frequency of urination in the treatment of overactive bladder. … It is marketed in Japan under the tradenames Staybla by Ono Pharmaceutical and Uritos by Kyojin Pharmaceutical.

  8. Drug

    EP-1043

    go.drugbank.com/drugs/DB06118
    Experimental

    The vaccine protein is adsorbed to Alhydrogel adjuvant and has been shown to effectively stimulate HTL responses against multiple epitopes in a mouse model. … EP-1043 is an epitope-based recombinant protein vaccine designed to induce HIV-1 specific helper T-lymphocyte (HTL) responses.

  9. Drug

    Dexmedetomidine

    go.drugbank.com/drugs/DB00633
    ApprovedInvestigationalVet approved

    An agonist of receptors, adrenergic alpha-2 that is used in veterinary medicine for its analgesic and sedative properties. It is the racemate of dexmedetomidine.

    Products: Dexmedetomidine in Dextrose, Dexmedetomidine Hydrochloride in Sodium Chloride
  10. Drug

    Anacaulase

    go.drugbank.com/drugs/DB17449
    ApprovedInvestigational

    Anacaulase (anacaulase-bcdb) is a mixture of proteolytic enzymes extracted from the stems of pineapple plants (_Ananas comosus_ [L.] Merr.). … [A256047,A256052,A256057] The EMA approved the use of anacaulase in 2013,[A256047,A256052] and in January 2023, anacaulase received FDA approval.[L44717]